Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore

Exclusion Criteria

• •Febrile illness (temperature \>= 37.5°C) or moderate or severe acute illness/infection on the day of the first vaccination, according to Investigator judgment.
• •For a woman of child-bearing potential, known pregnancy or positive urine pregnancy test on the day of inclusion.
• •Breast-feeding woman.
• •Known systemic hypersensitivity to any of the components of the trial vaccines (especially egg proteins or neomycin) or history of a life-threatening reaction to the trial vaccines or to a vaccine containing any of the same substances.
• •Personal or family history of thymic pathology or myasthenia.
• •Previous hepatitis A vaccination (for children only).
• •Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the past 6 months, or long-term systemic corticosteroid therapy.
• •Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the Investigator.
• •Receipt of blood or blood-derived products in the past 3 months that might interfere with the assessment of immune response.
• •Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination.
• •Planned participation in another clinical trial during the 18 coming months.
• •Receipt of any vaccine in the 4 weeks preceding the first trial vaccination.
• •Planned receipt of any vaccine in the 4 weeks following the first trial vaccination.
• •Participant deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent.
• •Current or past alcohol abuse or drug addiction that may interfere with the participants ability to comply with trial procedures.
• •Participant who plans to move to another country within the 18 coming months.